Oral povorcitinib promising in extensive nonsegmental vitiligo at week 52 in Phase 2b clinical trial Dr. Kamal Kant Kohli26 Oct 2023 10:30 AM ISTUSA: Treatment with oral povorcitinib in adult patients with extensive nonsegmental vitiligo was associated with substantial total body and facial...
Pfizer, MorphoSys and Incyte enter trial collaboration for Monjuvi in combination with TTI-622 Ruchika Sharma15 Jun 2022 10:00 AM ISTUnder the terms of the agreement, Pfizer will initiate a multicenter, international Phase 1b/2 study of TTI-622 with Monjuvi and lenalidomide for...
FIRST: Eli Lilly gets USFDA nod for alopecia areata pill Olumiant Ruchika Sharma14 Jun 2022 1:00 PM ISTOLUMIANT is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to Lilly and is available through specialty pharmacies nationwide.
USFDA nod to Eli Lilly Olumiant for certain hospitalized Covid patients Ruchika Sharma13 May 2022 1:02 PM ISTOLUMIANT is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to Lilly.
